PDCD1 and colorectal cancer: However, due to the high mutation burden, several clinical trials revealed a high response to anti-PD-1 antibodies in colorectal cancer with dMMR or high levels of MSI (MSI-H) compared to traditional treatments (53), suggesting that dMMR serves as useful indicator for choosing ICIs over other therapies.